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limit must be used to prevent further increases in mor-
tality rates for patients awaiting transplantation.
Moreover, the upper age limit used by most programs is
merely a guideline for selection. Age alone rarely dis-
qualifies patients from consideration. Chronologic age
certainly does not strictly correlate with physiologic age
in every case. The challenge for transplant physicians is
to establish objective parameters that accurately predict
the recipient’s response to the trauma of the operation
and the need for lifelong immunosuppression. 
The development of more specific immunosuppres-
sive drugs and the establishment of effective immune
tolerance protocols have the potential of reducing the
complications associated with immunosuppression that
seem to be more frequent and severe for elderly
patients. The future implementation of immunosuppres-
sive strategies based on pharmacogenomics may permit
the customization of drug therapy guided by the
patients’ genetic profiles and would be particularly ben-
eficial for elderly patients. 
Society must balance the issue of reducing death on
the waiting list with survival outcome after transplanta-
tion. The expansion of the donor supply with the use of
marginal hearts could reduce the chance of death for
patients awaiting transplantation. If the results of mar-
ginal donor hearts used for transplantation in patients
on alternative lists are comparable with the current
results with nonmarginal donor hearts, then those hearts
should be used for the lower-risk patients who are cur-
rently dying on the regular waiting list. The reality is
that for the foreseeable future the demand for hearts
will exceed the supply from the current donor pool even
with the liberal use of marginal, high-risk donor hearts.
Xenotransplantation, permanent mechanical support,
improved medical therapy, biventricular pacing, cellular
transplantation, and gene therapy are potential solutions
to the current donor heart shortage. Presently, perma-
nent mechanical support would seem to be the most fea-
sible treatment strategy for patients with end-stage heart
disease refractory to medical therapy. The results of
prospective trials such as the Randomized Evaluation of
Mechanical Assistance Therapy for Congestive Heart
Failure (REMATCH) study may provide the necessary
guidance for the use of this therapy for these patients. 
The objective of balancing the death of patients await-
ing transplantation with maximizing post-transplanta-
The results of cardiac transplantation in patients over69 years of age reported by Blanche and associates
demonstrate that short-term survival can be achieved in
a very select, small group of such patients. As the
authors have stated, the statistical comparison of this
small group of older patients to younger recipients is
problematic because the selection process was not uni-
form for both groups of patients. These data do not jus-
tify the elimination of older age as a selection criterion
for cardiac transplantation, because most reports identi-
fy increased recipient age as a risk factor for post-trans-
plantation mortality. Expanding the upper age limit will
result in a further distortion of the current recipient
demand/donor supply dilemma and will produce an
increased mortality for all patients awaiting cardiac
transplantation. The article by Blanche’s group does
raise many important moral, ethical, and practical
issues related to the treatment of patients with end-stage
heart disease.
The concept of an alternative list for older patients
seems rational but in turn introduces many theoretical
and practical concerns. Use of marginal donor hearts
for high-risk recipients seems likely to result in
reduced recipient survivals both in the immediate
post-transplantation period and in the long term. The
actuarial survival for patients after all other cardiac
surgical operations is influenced by the age of the
patient, and there is no logical reason why cardiac
transplantation should be different. There are also fac-
tors associated with long-term immunosuppression in
older patients that could be expected to adversely
influence survival and quality of life. 
The number of cardiac donors in this country has
remained static over the past 10 years despite intense
efforts at public education and the aggressive expansion
of acceptable donor criteria. Therefore, some upper age
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tion survival may be partially achieved by matching the
risk of marginal donor heart dysfunction with the
immunopathophysiologic function of the high-risk
recipients. The United Network for Organ Sharing
(UNOS) has made a policy decision regarding the use of
pediatric-age donor hearts for pediatric-age recipients.
This policy sets a precedent for the matching of the risks
donor heart function with recipient parameters. All
transplant physicians trying to decide whether to use a
specific donor heart for a potential recipient use this
concept on a daily basis. All of the donor data and recip-
ient conditions are analyzed in aggregate, and a decision
is rendered concerning proceeding with transplantation.
The consideration of all donor hearts including the mar-
ginal hearts for one list of recipients seems the most rea-
sonable paradigm. The creation of an alternate list
seems to disadvantage the patients on this list by giving
them second-rate hearts; conversely, if the hearts are
acceptable, then the standard list patients are disadvan-
taged by not being given the chance for the hearts. 
The definition of a “marginal” donor heart is fre-
quently in the eye of the beholder. Some of the donor
factors associated with this designation include female
sex, age over 45 years, dopamine support of greater
than 10 µg · kg–1 · min–1, body surface area of less than
70% of recipient body surface area, history of drug
abuse, diabetes mellitus, cardiac arrest, anticipated
graft ischemic time of more than 210 minutes, central
venous pressure of greater than 10 mm Hg, left ven-
tricular hypertrophy, ventricular dysfunction, risk fac-
tors for or the presence of coronary artery disease, and
hepatitis. Recipient factors associated with increased
risk of post-transplantation mortality include age over
50 years, pulmonary vascular resistance of more than
2.5 Wood units, male sex with a body surface area over
2.5 m2, more than one previous sternotomy, obesity,
diabetes mellitus, peripheral vascular disease, divertic-
ulosis, and a history of malignancy. The challenge to
match donor and recipient risks will continue until
more definitive data are available to guide the decision
about which heart should be given to which recipient.
On the basis of these observations, I would continue to
advocate responsible stewardship of the limited donor
resources and select the best candidates for transplan-
tation irrespective of patient age. The concept of estab-
lishing an alternative list should not be widely adopted
unless more convincing data are provided to support
this complex paradigm. 
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